mercurius-adept schreef op 20 november 2020 18:28:
mag ik ff peilen in welk scenario jullie hier nu nog het meest geloven /vertrouwen hebben?
Forward after that Type A meeting, Gilead may adjust its commercial stance in the US related to the marketing of filgotinib. Such actions could include
1. a full return of US commercial rights,
2. a decision to not pursue the RA indication, but continue to pursue the IBD indications,
3. or a decision to move ahead based on a positive outcome related to 200mg.
Van de Stolpe doesn’t believe Gilead will withdraw from filgotinib entirely should the 200mg dose not get FDA approved in the US for RA."
(vrij gejat uit recente MorganStanley analyse)